The DOI matches its Crossref record; 173 of the 173 references it cites were found in a registry or an index.
Metabolism and Disposition of Acetaminophen: Recent Advances in Relation to Hepatotoxicity and Diagnosis
Open accessAbstract
Acetaminophen (APAP) is one of the most widely used drugs. Though safe at therapeutic doses, overdose causes mitochondrial dysfunction and centrilobular necrosis in the liver. The first studies of APAP metabolism and activation were published more than 40 years ago. Most of the drug is eliminated by glucuronidation and sulfation. These reactions are catalyzed by UDP-glucuronosyltransferases (UGT1A1 and 1A6) and sulfotransferases (SULT1A1, 1A3/4, and 1E1), respectively. However, some is converted by CYP2E1 and other cytochrome P450 enzymes to a reactive intermediate that can bind to sulfhydryl groups. The metabolite can deplete liver glutathione (GSH) and modify cellular proteins. GSH binding occurs spontaneously, but may also involve GSH-S-transferases. Protein binding leads to oxidative stress and mitochondrial damage. The glucuronide, sulfate, and GSH conjugates are excreted by transporters in the canalicular (Mrp2 and Bcrp) and basolateral (Mrp3 and Mrp4) hepatocyte membranes. Conditions that interfere with metabolism and metabolic activation can alter the hepatotoxicity of the drug. Recent data providing novel insights into these processes, particularly in humans, are reviewed in the context of earlier work, and the effects of altered metabolism and reactive metabolite formation are discussed. Recent advances in the diagnostic use of serum adducts are covered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Antoine, D. J., Jenkins, R. E., Dear, J. W., Williams, D. P., McGill, M. R., Sharpe, M. R., Craig, D. G., Simpson, K. J., Jaeschke, H., & Park, B. K. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.019 · Cited by 309
Self-citationRetractedLarson, A. M., Polson, J., Fontana, R. J., Davern, T. J., Lalani, E., Hynan, L. S., Reisch, J. S., Schiødt, F. V., Ostapowicz, G., Shakil, A. O., et al. (2005) · Hepatology · doi:10.1002/hep.20948 · Cited by 1,926
Kaufman, D. W., Kelly, J. P., Rosenberg, L., Anderson, T. E., & Mitchell, A. A. (2002) · JAMA · doi:10.1001/jama.287.3.337 · Cited by 1,845 · cited 4×
“In fact, it is the most commonly used drug in the United States (1).”
InfluentialACETAMINOPHEN-INDUCED HEPATIC NECROSIS. IV. PROTECTIVE ROLE OF GLUTATHIONE
Mitchell, J. R., Jollow, D. J., Potter, W. Z., Gillette, J. R., & Brodie, B. B. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29666-5 · Cited by 1,737
ACETAMINOPHEN-INDUCED HEPATIC NECROSIS. I. ROLE OF DRUG METABOLISM
Mitchell, J. R., Jollow, D. J., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29663-x · Cited by 1,498
Infection of a human hepatoma cell line by hepatitis B virus
Gripon, P., Rumin, S., Urban, S., Le Seyec, J., Glaise, D., Cannie, I., Guyomard, C., Lucas, J., Trepo, C., & Guguen-Guillouzo, C. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.232137699 · Cited by 1,282
ACETAMINOPHEN-INDUCED HEPATIC NECROSIS. II. ROLE OF COVALENT BINDING IN VIVO
Jollow, D. J., Mitchell, J. R., Potter, W. Z., Davis, D. C., Gillette, J. R., & Brodie, B. B. (1973) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)29664-1 · Cited by 1,204
Acetaminophen-induced Hepatic Necrosis
Jollow, D. J., Thorgeirsson, S. S., Potter, W. Z., Hashimoto, M., & Mitchell, J. R. (1974) · Pharmacology · doi:10.1159/000136547 · Cited by 1,092
N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen.
Dahlin, D. C., Miwa, G. T., Lu, A. Y., & Nelson, S. D. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.5.1327 · Cited by 1,078
Jaeschke, H., McGill, M. R., & Ramachandran, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.602688 · Cited by 964
Self-citation
Cited by
Bruderer, R., Bernhardt, O. M., Gandhi, T., Miladinović, S. M., Cheng, L.-Y., Messner, S., Ehrenberger, T., Zanotelli, V., Butscheid, Y., Escher, C., et al. (2015) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m114.044305 · Cited by 1,238
Acetaminophen-Induced Hepatotoxicity: a Comprehensive Update
(2016) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2015.00052 · Cited by 744
Shuhendler, A. J., Pu, K., Cui, L., Uetrecht, J. P., & Rao, J. (2014) · Nature Biotechnology · doi:10.1038/nbt.2838 · Cited by 623
Du, K., Ramachandran, A., & Jaeschke, H. (2016) · Redox Biology · doi:10.1016/j.redox.2016.10.001 · Cited by 569
Self-citationDrug-induced liver injury: recent advances in diagnosis and risk assessment
Kullak-Ublick, G. A., Andrade, R. J., Merz, M., End, P., Benesic, A., Gerbes, A. L., & Aithal, G. P. (2017) · Gut · doi:10.1136/gutjnl-2016-313369 · Cited by 438
PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses
Mazaleuskaya, L. L., Sangkuhl, K., Thorn, C. F., FitzGerald, G. A., Altman, R. B., & Klein, T. E. (2015) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000150 · Cited by 379
Ramachandran, A., & Jaeschke, H. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1679919 · Cited by 326
Self-citationRaghu, G., Berk, M., Campochiaro, P. A., Jaeschke, H., Marenzi, G., Richeldi, L., Wen, F.-Q., Nicoletti, F., & Calverley, P. M. A. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666201230144109 · Cited by 280
Self-citationRole and Mechanisms of Mitophagy in Liver Diseases
Ma, X., McKeen, T., Zhang, J., & Ding, W.-X. (2020) · Cells · doi:10.3390/cells9040837 · Cited by 279
Ellagic acid: Pharmacological activities and molecular mechanisms involved in liver protection
García-Niño, W. R., & Zazueta, C. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.04.008 · Cited by 274
Liu, X. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-7647-4_2 · Cited by 254
Acetaminophen/paracetamol: A history of errors, failures and false decisions
Brune, K., Renner, B., & Tiegs, G. (2015) · European Journal of Pain · doi:10.1002/ejp.621 · Cited by 213
McGill, M. R., Staggs, V. S., Sharpe, M. R., Lee, W. M., & Jaeschke, H. (2014) · Hepatology · doi:10.1002/hep.27265 · Cited by 148
Self-citationA critical perspective on 3D liver models for drug metabolism and toxicology studies
Serras, A. S., Rodrigues, J. S., Cipriano, M., Rodrigues, A. V., Oliveira, N. G., & Miranda, J. P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.626805 · Cited by 138
Pimpão, R. C., Ventura, M. R., Ferreira, R. B., Williamson, G., & Santos, C. N. (2015) · British Journal of Nutrition · doi:10.1017/s0007114514003511 · Cited by 126
Can paracetamol (acetaminophen) be administered to patients with liver impairment?
Hayward, K. L., Powell, E. E., Irvine, K. M., & Martin, J. H. (2016) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12802 · Cited by 104
Benesic, A., Leitl, A., & Gerbes, A. L. (2016) · Gut · doi:10.1136/gutjnl-2015-309528 · Cited by 48
Sun, J., Wen, Y., Zhou, Y., Jiang, Y., Chen, Y., Zhang, H., Guan, L., Yao, X., Huang, M., & Bi, H. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0507-z · Cited by 44
Ray, S., Salzer, I., Kronschläger, M. T., & Boehm, S. (2019) · Pain · doi:10.1097/j.pain.0000000000001474 · Cited by 35
“(NAPQI), which is known to mediate hepatotoxicity after paracetamol over dosage.(34) Less than 0.”
The effects of fasting on drug metabolism
Lammers, L. A., Achterbergh, R., Mathôt, R. A. A., & Romijn, J. A. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1706728 · Cited by 32
“UGT1A1 is also involved in acetaminophen (paracetamol) metabolism [15].”
BackgroundInvestigating acetaminophen hepatotoxicity in multi-cellular organotypic liver models
Orbach, S. M., Cassin, M. E., Ehrich, M. F., & Rajagopalan, P. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.03.008 · Cited by 28
Old problem, new solutions: biomarker discovery for acetaminophen liver toxicity
Gloor, Y., Schvartz, D., & F.Samer, C. (2019) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2019.1642323 · Cited by 18
“Administration of N-acetyl-cysteine (NAC) can restore intracellular pools of GSH and is therefore an antidote of choice in case of acetaminophen intoxication [10,25,34].”
BackgroundMethodYou, K., Wang, Y., Chen, X., Yang, Z., Chen, Y., Tan, S., Tao, J., Getachew, A., Pan, T., Xu, Y., et al. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.11.079 · Cited by 9
Metadata
- Authors
- McGill, M. R., & Jaeschke, H.
- Venue
- Pharmaceutical Research
- Published
- 2013-03-06
- Volume
- 30
- Issue
- 9
- Pages
- 2174-2187
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W2059655597
- Cited by
- 704
- References
- 173
- FWCI
- 37.95
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.